trending Market Intelligence /marketintelligence/en/news-insights/trending/jhe7dnmofbcnm_khqzm7sg2 content esgSubNav
In This List

Cipher acquires Canadian rights to Synergy's constipation treatment

Blog

A Pharmaceutical Company Capitalizes on M&A Activity with Brokerage Research

Blog

2021 Year in Review: Highlighting Key Investment Banking Trends

Blog

Insight Weekly: US stock performance; banks' M&A risk; COVID-19 vaccine makers' earnings

Blog

Global M&A By the Numbers: Q3 2021


Cipher acquires Canadian rights to Synergy's constipation treatment

Canada-based Cipher Pharmaceuticals Inc. has acquired exclusive Canadian marketing and selling rights to Synergy Pharmaceuticals Inc.'s constipation treatment Trulance for an upfront payment of $5.0 million.

Synergy will also receive certain milestone payment and royalties on future sales of the drug in Canada. The New York-based biotechnology company will manufacture and supply the finished product to Cipher.

Trulance is approved by the U.S. Food and Drug Administration to treat adults with chronic idiopathic constipation and irritable bowel syndrome with constipation.